Jacquie Astemborski

Jacquie Astemborski

Auto-generated profile, based on publicly available information

Jacquie Astemborski

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

11 March 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MBMegan Buresh
Megan Buresh
RGRachel E Gicquelais
Rachel E Gicquelais
JAJacquie Astemborski
Jacquie Astemborski
GKGregory D Kirk
Gregory D Kirk
SMShruti H Mehta
Shruti H Mehta
BGBecky L Genberg
Becky L Genberg
Overdose is a leading cause of death in the United States, especially among people who inject drugs (PWID). Improving naloxone access and carrying among PWID may offset recent increases in overdose mortality associated with the influx of synthetic opioids in the drug market. This study characterized prevalence and correlates of several naloxone outcomes among PWID. During 2018, a survey to assess experience with naloxone was administered to 915 participants in the AIDS Linked to the IntraVenous Experience (ALIVE) study, an ongoing community-based observational cohort of people who currently inject or formerly injected drugs in Baltimore, Maryland. We examined the associations of naloxone outcomes (training, supply, use, and regular possession) with socio-demographic, substance use and healthcare utilization factors among PWID in order to characterize gaps in naloxone implementation among this high-risk population. Median age was 56 years, 34% were female, 85% were African American, and 31% recently injected. In the past six months, 46% (n = 421) reported receiving training in overdose prevention, 38% (n = 346) had received a supply of naloxone, 9% (n = 85) had administered naloxone, and 9% (n = 82) reported usually carrying a supply of naloxone. Recent non-fatal overdose was not associated with any naloxone outcomes in adjusted analysis. Active opioid use (aOR = 2.10, 95% CI: 1.03, 4.28) and recent treatment of alcohol or substance use disorder (aOR = 2.01, 95% CI: 1.13, 3.56) were associated with regularly carrying naloxone. Further work is needed to encourage PWID to carry and effectively use naloxone to decrease rates of fatal opioid overdose. While accessing treatment for substance use disorder was positively associated with carrying naloxone, EMS response to 911 calls for overdose, the emergency department, and syringe services programs may be settings in which naloxone access and carrying could be encouraged among PWID.

1 December 2019 in International Journal of Drug Policy
Verified
Journal Article
Closed access
MBMegan Buresh
Megan Buresh
BGBecky L. Genberg
Becky L. Genberg
JAJacquie Astemborski
Jacquie Astemborski
GKGregory D. Kirk
Gregory D. Kirk
SMShruti H. Mehta
Shruti H. Mehta

13 February 2012 in Hepatology
Verified
Journal Article
Open access
PDF file
SMSupriya Munshaw
Supriya Munshaw
HHHyon S. Hwang
Hyon S. Hwang
MTMichael S. Torbenson
Michael S. Torbenson
JQJeffrey Quinn
Jeffrey Quinn
KHKasper D. Hansen
Kasper D. Hansen
ABAshwin Balagopal
Ashwin Balagopal
Chronic hepatitis C virus (HCV) infection is complicated by hepatic fibrosis. Hypothesizing that early fibrogenic signals may originate in cells susceptible to HCV infection, hepatocyte gene expression was analyzed from persons with chronic HCV at different stages of liver fibrosis. Four HCV-infected subjects with precirrhosis liver fibrosis (Ishak fibrosis 3-5) were matched for age, race, and gender to five HCV-infected subjects with no evidence of fibrosis (Ishak fibrosis 0). Hepatocytes from each subject were isolated from liver biopsies using laser capture microdissection. Transcriptome profiling was performed on hepatocyte RNA using hybridization arrays. We found that hepatocytes in precirrhosis fibrosis were depleted for genes involved in small molecule and drug metabolism, especially butyrylcholinesterase (BCHE), a gene involved in the metabolism of drugs of abuse. Differential expression ofBCHEwas validated in the same tissues and cross-sectionally in an expanded cohort of 143 HCV-infected individuals. In a longitudinal study, serum BCHE activity was already decreased at study inception in 19 fibrosis progressors compared with 20 fibrosis nonprogressors (P< 0.05). Nonprogressors also had decreased BCHE activity over time compared with initial values, but these evolved a median (range) 8.6 (7.8-11.4) years after the study period inception (P< 0.05). Laser captured portal tracts were enriched for immune related genes when compared with hepatocytes but precirrhosis livers lost this enrichment.Conclusion: Chronic HCV is associated with hepatocyteBCHEloss years before hepatic synthetic function is impaired. These results indicate thatBCHEmay be involved in the pathogenesis of HCV-related fibrosis among injection drug users. (HEPATOLOGY 2012)

12 July 2022 in Annals of Internal Medicine
Verified
Journal Article
Closed access
JCJavier A. Cepeda
Javier A. Cepeda
DTDavid L. Thomas
David L. Thomas
JAJacqueline Astemborski
Jacqueline Astemborski
JRJacqueline E. Rudolph
Jacqueline E. Rudolph
RGRachel Gicquelais
Rachel Gicquelais
SMShruti H. Mehta
Shruti H. Mehta
The World Health Organization has called for the elimination of hepatitis C virus (HCV) infection by 2030. However, historically low uptake of HCV treatment among people who inject drugs (PWID) thr... Visual Impact of Hepatitis C Treatment Uptake on Cirrhosis and Mortality. The World Health Organization has called for the elimination of hepatitis C virus (HCV) infection by 2030. However... Background: Hepatitis C virus (HCV) infection can be cured, and the United States has joined the World Health Organization in calling for HCV elimination by 2030. However, historically low uptake o...

1 November 2019 in Journal of Substance Abuse Treatment
Verified
Journal Article
Closed access
BGBecky L. Genberg
Becky L. Genberg
JAJacquie Astemborski
Jacquie Astemborski
GTGlenn J Treisman
Glenn J Treisman
AAAlexia Alexia Anagnostopoulos
Alexia Alexia Anagnostopoulos
SMShruti H. Mehta
Shruti H. Mehta
AAAlison G. Abraham
Alison G. Abraham